Found: 4
Select item for more details and to access through your institution.
Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 4, p. 573, doi. 10.1177/13524585211032348
- By:
- Publication type:
- Article
Human Peripheral Blood Mononuclear Cells Exhibit Heterogeneous CD52 Expression Levels and Show Differential Sensitivity to Alemtuzumab Mediated Cytolysis.
- Published in:
- PLoS ONE, 2012, v. 7, n. 6, p. 1, doi. 10.1371/journal.pone.0039416
- By:
- Publication type:
- Article
Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function.
- Published in:
- Biotechnology & Bioengineering, 2008, v. 99, n. 3, p. 652, doi. 10.1002/bit.21598
- By:
- Publication type:
- Article
Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro.
- Published in:
- Immunology, 2014, v. 141, n. 1, p. 123, doi. 10.1111/imm.12178
- By:
- Publication type:
- Article